ClinicalTrials.gg
Not yet recruitingNCT07147946Updated Sep 10, 2025

Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of TQC3721 Suspension for inhalation and Placebo of TQC3721 Suspension for Inhalation in Chronic Obstructive Pulmonary Disease, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 76 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
666
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.

Planned enrollment
2nd of 17
666 · median 113
Started
2025
with 4 others
Phase 3
2 of 17
2 open now
Registered
13th of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2025, is one of 2 in phase 3, and was the 13th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

To evaluate the efficacy of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign an form before screening and fully understand the trial content, process, and potential adverse reactions.
  2. Comply with the experimental schedule and be able to use the nebulizer inhaler correctly.
  3. The age range is 40 to 80 years old (including the threshold), and both male and female participants are eligible.
  4. The subjects have no pregnancy plans and voluntarily take effective measures for at least one month from screening to the last use of the study drug.
  5. Patients with a clear clinical history and related symptoms of before screening.
  6. Capable of conducting acceptable and reproducible lung function tests.
  7. COPD clinical stability (no moderate to severe COPD acute exacerbation) within the 4 weeks prior to screening visit (V1 visit) and between V1 visit and V2 visit.
  8. Smoking history ≥ 10 pack years.

Exclusion criteria

Exclusion Criteria:

  1. A history of life-threatening , including admission to the intensive care unit and/or the need for intubation.
  2. COPD acute exacerbations requiring systemic hormone therapy within 3 months prior to screening visit (V1 visit) or prior to randomization visit (V2 visit).
  3. Within the first 6 months of screening, there has been at least 1 hospitalization history due to acute exacerbation of COPD or pneumonia.
  4. Treatment with antibiotics for upper and/or lower respiratory tract infections within 6 weeks prior to screening or randomization visit (V3 visit).
  5. Simultaneously suffering from other respiratory diseases.
  6. Chest computed tomography (CT) revealed abnormalities and concluded that the abnormalities were not caused by COPD.
  7. Previous lung resection or lung reduction surgery.

11.Previously received TQC3721 treatment. 12.Patients who received therapy within 4 weeks prior to the screening period 13.In the investigator's assessment, patients are unable to discontinue the prohibited drugs specified in the protocol during the screening and treatment phases of the study; 14.Patients with a history of uncontrolled current diseases that the investigator judges to be clinically significant; 15.A history or current evidence of clinically significant cardiovascular or cerebrovascular diseases; 16.A history of malignant tumors (cured or uncured) in any organ or system within the past 5 years; 17.Intolerance or allergy to salbutamol or other inhaled bronchodilator therapies for COPD; 18.Patients requiring long-term oxygen therapy; 19.Female subjects who are currently pregnant, breastfeeding, or planning to become pregnant during the study period after enrollment; 20.Having participated in any clinical trial of drugs or medical devices within 4 weeks or 5 half-lives (whichever is longer) prior to the screening visit; 21.Other conditions deemed unsuitable for participation in the study by the investigator.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
666 participants (estimated)

Study arms

  • Experimental
    TQC3721 Suspension for Inhalation

    Inhalation of TQC3721 suspension (6mg/2ml), one unit dose twice daily for 24 weeks

    Drug: TQC3721 Suspension for inhalation

  • Placebo comparator
    Placebo of TQC3721 Suspension for Inhalation

    Inhalation of TQC3721 placebo, one unit dose twice daily for 24 weeks

    Drug: Placebo of TQC3721 Suspension for Inhalation

Interventions

  • TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor

  • DrugPlacebo of TQC3721 Suspension for Inhalation

    Placebo without drug substance

06

What researchers measure

Primary outcomes

  1. Mean change in the area under the curve (AUC) of Forced Expiratory Volume in 1 second (FEV1)

    Change from baseline in mean FEV1 AUC over 0-12 hours after 12 weeks of treatment.

    Time frame: Baseline to 12 weeks after treatment

Secondary outcomes

  1. Changes in peak FEV1 value

    Changes from baseline in peak FEV1 within 4 hours after morning dosing at Weeks 6, 12, and 24 of treatment.

    Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment

  2. Changes in trough FEV1 values

    Changes from baseline in morning trough FEV1 at Weeks 6, 12, and 24 of treatment.

    Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment

  3. Average FEV1 AUC 0-4h

    Change from baseline in the average FEV1 AUC 0-4h within 4 hours after morning dosing at 6, 12, and 24 weeks of treatment.

    Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment

  4. St. George's Respiratory Questionnaire

    Changes in St. George's Respiratory Questionnaire (SGRQ) total scores from baseline at 6, 12, and 24 weeks of treatment.

    Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment

  5. Chronic Obstructive Pulmonary Disease Assessment Test

    Self-assessment for Patients with COPD:Numbers 0 to 5 indicate the severity (with 0 being the mildest and 5 being the most severe).

    Time frame: At 6 weeks, 12 weeks, and 24 weeks of treatment

  6. Average FEV1 AUC (6-12h)

    Change from baseline in mean FEV₁ AUC (6-12 h) at Week 12 following dosing.

    Time frame: Baseline to 12 weeks after treatment

  7. Annual rate of acute exacerbation of COPD

    The annualized rate of acute exacerbation of moderate/severe COPD after 24 weeks of treatment.

    Time frame: Baseline to 24 weeks after treatment

  8. Time of first acute exacerbation of moderate/severe COPD

    The time of the first acute exacerbation of moderate/severe COPD within 24 weeks of treatment.

    Time frame: Baseline to 24 weeks after treatment

  9. Adverse event (AE)

    The number of participants with AEs, serious dverse event (SAEs), drug-related AEs, and abnormal lab results.

    Time frame: D-28 to within 25 weeks of treatment

  10. Assessment of respiratory symptoms in COPD

    Change from baseline in weekly mean Evaluating Respiratory Symptoms in COPD total score

    Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment

  11. Transition Dyspnea Index (TDI) score

    Change in Transition Dyspnea Index (TDI) score relative to Baseline Dyspnea Index (BDI) score

    Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment

  12. Chronic Obstructive Pulmonary Disease Assessment Test (CAT) score

    Change in Chronic Obstructive Pulmonary Disease Assessment Test (CAT) score from baseline

    Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment

  13. Change from baseline in rescue medication use

    Changes from baseline in rescue medication use during treatment at Weeks 6, 12, and 24 versus the placebo group

    Time frame: Baseline to 6 weeks, 12 weeks, 24 weeks after treatment.

  14. Interleukin-6 (IL-6), Interleukin-8 (IL-8), and C-reactive protein (CRP) at Week 12 and Week 24

    IL-6, IL-8, and C-reactive protein (CRP) at Week 12 and Week 24. The elevated serum C-reactive protein (CRP) levels in patients with chronic obstructive pulmonary disease (COPD) are primarily associated with pulmonary inflammatory responses.

    Time frame: At Week 12 and Week 24

  15. Plasma drug peak concentration

    Perform Pharmacokinetics (PK) analysis of TQC3721 blood drug concentration data at baseline, week 6, and week 12 to evaluate the PK characteristics of TQC3721 in COPD patients.

    Time frame: Day 1: 0.5 hour after-dose, Week 6: 1 hour pre-dose, 0.5 hour after-dose; Week 12: 1 hour pre-dose, 0.5 hour after-dose

07

Study locations

76 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Mar 2027, 18 months later.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 18 months is close to that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Aug 29, 2025
StartEst.
Sep 2025
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07147946
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Sep 2025 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 10, 2025

Study contacts

Weimin Li, Doctor
Contact
weimin003@163.com
028-85423998

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC3721

Start the discussion